Physician profile
Ahmed Galal
NPI 1902179906
$1,697,807.59
in general payments reported to CMS, 2019-2025
35 companies · $238K in 2025
The $238K reported for 2025 was more than what 99% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342K · 2020: $169K · 2021: $253K · 2022: $274K · 2023: $262K · 2024: $160K · 2025: $238K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $502K · Travel and Lodging: $115K · Consulting Fee: $36K · Food and Beverage: $7,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $501,940.15 |
| Travel and Lodging | $114,882.55 |
| Consulting Fee | $35,695.00 |
| Food and Beverage | $7,299.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $732,626.12 | 2019-2025 | Jakafi, Monjuvi, Monjuvi |
| Kite Pharma, INC. | $440,353.24 | 2019-2025 | Yescarta |
| Seagen INC. | $117,645.20 | 2019-2023 | Adcetris |
| Beigene USA, INC. | $83,347.63 | 2020-2024 | Brukinsa |
| Celgene Corporation | $58,590.27 | 2019-2025 | Breyanzi |
| Mallinckrodt Hospital Products INC. | $57,301.36 | 2022-2023 | Uvadex |
| Epizyme, INC. | $37,147.47 | 2020-2021 | |
| Pfizer INC. | $33,879.46 | 2024-2025 | |
| Therakos LLC | $32,659.08 | 2025 | Cellex, Uvadex |
| Eusa Pharma (US) LLC | $32,445.30 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $23,713.60 | 2019 | |
| Kyowa Kirin, INC. | $23,090.83 | 2019-2024 | Poteligeo |
| Novartis Pharmaceuticals Corporation | $12,180.53 | 2019-2025 | Kymriah |
| Verastem, INC. | $5,377.67 | 2019 | |
| Agios Pharmaceuticals, INC. | $3,859.61 | 2019-2024 | Pyrukynd |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $1,937.50 | 2020 | |
| Stryker Corporation | $384.56 | 2019 | |
| Genentech USA, INC. | $263.44 | 2019-2025 | Polivy, Lunsumio, Columvi |
| Janssen Biotech, INC. | $214.45 | 2024-2025 | Carvykti, Darzalex, Tecvayli |
| Gilead Sciences, INC. | $150.00 | 2025 | |
| Adc Therapeutics America, INC. | $129.55 | 2024 | |
| Secura Bio, INC. | $122.42 | 2025 | Copiktra |
| Abbvie INC. | $99.39 | 2024-2025 | |
| Beone Medicines USA, INC. | $50.44 | 2025 | Brukinsa |
| Adaptive Biotechnologies Corporation | $46.60 | 2024-2025 | Clonoseq |
| Genzyme Corporation | $40.41 | 2025 | |
| Glaxosmithkline, LLC. | $39.37 | 2025 | Zejula, Jemperli, Ojjaara |
| Sanofi-Aventis U.S. LLC | $23.00 | 2025 | |
| Recordati_rare_diseases_inc. | $19.06 | 2025 | Sylvant |
| Daiichi Sankyo INC. | $18.53 | 2024 | Enhertu |
| Legend Biotech USA INC. | $17.59 | 2024 | |
| Pharmacosmos Therapeutics INC. | $17.39 | 2025 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $16.52 | 2025 | Tazverik |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Galal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.